Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy

Omar Picado, Kristina Khazeni, Casey Allen, Danny Yakoub, Eli Avisar, Susan B. Kesmodel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Management of the axilla in patients with early-stage breast cancer (ESBC) has evolved. Recent trials support less extensive axillary surgery in patients undergoing mastectomy. We examine factors affecting regional lymph node (RLN) surgery and outcomes in patients with ESBC undergoing mastectomy. Methods: Women with clinical T1/2 N0 M0 invasive BC who underwent mastectomy with 1–2 positive nodes were selected from the National Cancer Database (2004–2015). Axillary surgery was defined by number of RLNs examined: 1–5 sentinel LN dissection (SLND), and ≥ 10 axillary LND (ALND). Binary logistic regression and survival analyses were performed to assess the association between axillary surgery and clinical characteristics, and overall survival (OS), respectively. Results: 34,243 patients were included: 13,821 SLND (40%) and 20,422 ALND (60%). SLND significantly increased from 21% (2004) to 45% (2015) (p <.001). Independent factors associated with SLND were treatment year, non-Academic centers, geographic region, tumor histology, and postmastectomy radiotherapy (PMRT). Multivariable survival analysis showed that ALND was associated with better OS (HR 0.78, 95% CI 0.72–0.83, p <.001) relative to SLND; however, there was no difference in patients with LN micrometastases treated without RT (HR 0.87, 95% CI 0.73–1.05, p =.153) or patients receiving PMRT (HR 0.92, 95% CI 0.76–1.13, p =.433). Conclusions: SLND has significantly increased in patients undergoing mastectomy with limited axillary disease and is influenced by patient, tumor, and treatment factors. Survival outcomes did not differ by axillary treatment for patients with LN micrometastases treated without RT or patients who received PMRT. SLND may be considered in select patients with ESBC and limited axillary disease undergoing mastectomy.

Original languageEnglish (US)
Pages (from-to)461-469
Number of pages9
JournalBreast Cancer Research and Treatment
Volume171
Issue number2
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Mastectomy
Lymph Nodes
Breast Neoplasms
Dissection
Neoplasm Micrometastasis
Radiotherapy
Survival Analysis
Survival
Neoplasms
Axilla
cyhalothrin
Histology
Therapeutics
Logistic Models
Regression Analysis
Databases

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy. / Picado, Omar; Khazeni, Kristina; Allen, Casey; Yakoub, Danny; Avisar, Eli; Kesmodel, Susan B.

In: Breast Cancer Research and Treatment, Vol. 171, No. 2, 01.09.2018, p. 461-469.

Research output: Contribution to journalArticle

@article{ac44494121ce4ec889b66cc726faecb0,
title = "Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy",
abstract = "Purpose: Management of the axilla in patients with early-stage breast cancer (ESBC) has evolved. Recent trials support less extensive axillary surgery in patients undergoing mastectomy. We examine factors affecting regional lymph node (RLN) surgery and outcomes in patients with ESBC undergoing mastectomy. Methods: Women with clinical T1/2 N0 M0 invasive BC who underwent mastectomy with 1–2 positive nodes were selected from the National Cancer Database (2004–2015). Axillary surgery was defined by number of RLNs examined: 1–5 sentinel LN dissection (SLND), and ≥ 10 axillary LND (ALND). Binary logistic regression and survival analyses were performed to assess the association between axillary surgery and clinical characteristics, and overall survival (OS), respectively. Results: 34,243 patients were included: 13,821 SLND (40{\%}) and 20,422 ALND (60{\%}). SLND significantly increased from 21{\%} (2004) to 45{\%} (2015) (p <.001). Independent factors associated with SLND were treatment year, non-Academic centers, geographic region, tumor histology, and postmastectomy radiotherapy (PMRT). Multivariable survival analysis showed that ALND was associated with better OS (HR 0.78, 95{\%} CI 0.72–0.83, p <.001) relative to SLND; however, there was no difference in patients with LN micrometastases treated without RT (HR 0.87, 95{\%} CI 0.73–1.05, p =.153) or patients receiving PMRT (HR 0.92, 95{\%} CI 0.76–1.13, p =.433). Conclusions: SLND has significantly increased in patients undergoing mastectomy with limited axillary disease and is influenced by patient, tumor, and treatment factors. Survival outcomes did not differ by axillary treatment for patients with LN micrometastases treated without RT or patients who received PMRT. SLND may be considered in select patients with ESBC and limited axillary disease undergoing mastectomy.",
author = "Omar Picado and Kristina Khazeni and Casey Allen and Danny Yakoub and Eli Avisar and Kesmodel, {Susan B.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s10549-018-4840-9",
language = "English (US)",
volume = "171",
pages = "461--469",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy

AU - Picado, Omar

AU - Khazeni, Kristina

AU - Allen, Casey

AU - Yakoub, Danny

AU - Avisar, Eli

AU - Kesmodel, Susan B.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: Management of the axilla in patients with early-stage breast cancer (ESBC) has evolved. Recent trials support less extensive axillary surgery in patients undergoing mastectomy. We examine factors affecting regional lymph node (RLN) surgery and outcomes in patients with ESBC undergoing mastectomy. Methods: Women with clinical T1/2 N0 M0 invasive BC who underwent mastectomy with 1–2 positive nodes were selected from the National Cancer Database (2004–2015). Axillary surgery was defined by number of RLNs examined: 1–5 sentinel LN dissection (SLND), and ≥ 10 axillary LND (ALND). Binary logistic regression and survival analyses were performed to assess the association between axillary surgery and clinical characteristics, and overall survival (OS), respectively. Results: 34,243 patients were included: 13,821 SLND (40%) and 20,422 ALND (60%). SLND significantly increased from 21% (2004) to 45% (2015) (p <.001). Independent factors associated with SLND were treatment year, non-Academic centers, geographic region, tumor histology, and postmastectomy radiotherapy (PMRT). Multivariable survival analysis showed that ALND was associated with better OS (HR 0.78, 95% CI 0.72–0.83, p <.001) relative to SLND; however, there was no difference in patients with LN micrometastases treated without RT (HR 0.87, 95% CI 0.73–1.05, p =.153) or patients receiving PMRT (HR 0.92, 95% CI 0.76–1.13, p =.433). Conclusions: SLND has significantly increased in patients undergoing mastectomy with limited axillary disease and is influenced by patient, tumor, and treatment factors. Survival outcomes did not differ by axillary treatment for patients with LN micrometastases treated without RT or patients who received PMRT. SLND may be considered in select patients with ESBC and limited axillary disease undergoing mastectomy.

AB - Purpose: Management of the axilla in patients with early-stage breast cancer (ESBC) has evolved. Recent trials support less extensive axillary surgery in patients undergoing mastectomy. We examine factors affecting regional lymph node (RLN) surgery and outcomes in patients with ESBC undergoing mastectomy. Methods: Women with clinical T1/2 N0 M0 invasive BC who underwent mastectomy with 1–2 positive nodes were selected from the National Cancer Database (2004–2015). Axillary surgery was defined by number of RLNs examined: 1–5 sentinel LN dissection (SLND), and ≥ 10 axillary LND (ALND). Binary logistic regression and survival analyses were performed to assess the association between axillary surgery and clinical characteristics, and overall survival (OS), respectively. Results: 34,243 patients were included: 13,821 SLND (40%) and 20,422 ALND (60%). SLND significantly increased from 21% (2004) to 45% (2015) (p <.001). Independent factors associated with SLND were treatment year, non-Academic centers, geographic region, tumor histology, and postmastectomy radiotherapy (PMRT). Multivariable survival analysis showed that ALND was associated with better OS (HR 0.78, 95% CI 0.72–0.83, p <.001) relative to SLND; however, there was no difference in patients with LN micrometastases treated without RT (HR 0.87, 95% CI 0.73–1.05, p =.153) or patients receiving PMRT (HR 0.92, 95% CI 0.76–1.13, p =.433). Conclusions: SLND has significantly increased in patients undergoing mastectomy with limited axillary disease and is influenced by patient, tumor, and treatment factors. Survival outcomes did not differ by axillary treatment for patients with LN micrometastases treated without RT or patients who received PMRT. SLND may be considered in select patients with ESBC and limited axillary disease undergoing mastectomy.

UR - http://www.scopus.com/inward/record.url?scp=85048042566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048042566&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4840-9

DO - 10.1007/s10549-018-4840-9

M3 - Article

VL - 171

SP - 461

EP - 469

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -